Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LP_LDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LP_LDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.

LP_LDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-

• Profit share of the sale of the strain as an ingredient by Sacco
• Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners

This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LP_LDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LP_LDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LP_LDL® in the US, Asian and other international markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LP_LDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LP_LDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.

LP_LDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-

• Profit share of the sale of the strain as an ingredient by Sacco
• Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners

This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LP_LDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LP_LDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LP_LDL® in the US, Asian and other international markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LP_LDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LP_LDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.

LP_LDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-

• Profit share of the sale of the strain as an ingredient by Sacco
• Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners

This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LP_LDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LP_LDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LP_LDL® in the US, Asian and other international markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LP_LDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LP_LDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.

LP_LDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-

• Profit share of the sale of the strain as an ingredient by Sacco
• Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners

This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LP_LDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LP_LDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LP_LDL® in the US, Asian and other international markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LP_LDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LP_LDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.

LP_LDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-

• Profit share of the sale of the strain as an ingredient by Sacco
• Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners

This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LP_LDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LP_LDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LP_LDL® in the US, Asian and other international markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a manufacturing and supply agreement with Sacco S.r.l., ("Sacco"). The agreement grants Sacco an exclusive licence to manufacture and supply OptiBiotix's cholesterol reducing strain, LP_LDL®, in Europe in return for 50% of the profit with a minimum price per kilogramme to secure against discounting.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best selling probiotic strains, to over 2,500 businesses across Europe. Under the terms of the agreement, Sacco will promote and expand the supply of LP_LDL® throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.

LP_LDL® will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations. These will be subject to separate license agreements creating the opportunity for multiple revenue streams at different points in the value chain arising from:-

• Profit share of the sale of the strain as an ingredient by Sacco
• Royalties from the sale of higher value white label formulations, and branded products from consumer healthcare and pharmaceutical partners

This agreement is the first step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's brand portfolio and market reach to serve consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply, and profit sharing agreement with Sacco, one of Europe's leading suppliers of probiotics ingredients. We chose Sacco due to their industry reputation, extensive European network and track record in building sales for what have become some of the world's best selling probiotic strains. We believe that OptiBiotix's strong supporting science, and growing industry awareness of our LP_LDL® cholesterol and blood pressure reducing strain, has created a high level of interest in using LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products. We believe working with Sacco, and similar partners around the world, provide the best opportunity of building LP_LDL® into a global brand. Discussions are progressing with corporate partners for the manufacture and supply of products containing LP_LDL® in the US, Asian and other international markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.